HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nitroalkene fatty acids modulate bile acid metabolism and lung function in obese asthma.

Abstract
Bile acid profiles are altered in obese individuals with asthma. Thus, we sought to better understand how obesity-related systemic changes contribute to lung pathophysiology. We also test the therapeutic potential of nitro-oleic acid (NO2-OA), a regulator of metabolic and inflammatory signaling pathways, to mitigate allergen and obesity-induced lung function decline in a murine model of asthma. Bile acids were measured in the plasma of healthy subjects and individuals with asthma and serum and lung tissue of mice with and without allergic airway disease (AAD). Lung function, indices of inflammation and hepatic bile acid enzyme expression were measured in obese mice with house dust mite-induced AAD treated with vehicle or NO2-OA. Serum levels of glycocholic acid and glycoursodeoxycholic acid clinically correlate with body mass index and airway hyperreactivity whereas murine levels of β-muricholic acid and tauro-β-muricholic acid were significantly increased and positively correlated with impaired lung function in obese mice with AAD. NO2-OA reduced murine bile acid levels by modulating hepatic expression of bile acid synthesis enzymes, with a concomitant reduction in small airway resistance and tissue elastance. Bile acids correlate to body mass index and lung function decline and the signaling actions of nitroalkenes can limit AAD by modulating bile acid metabolism, revealing a potential pharmacologic approach to improving the current standard of care.
AuthorsMichelle L Manni, Victoria A Heinrich, Gregory J Buchan, James P O'Brien, Crystal Uvalle, Veronika Cechova, Adolf Koudelka, Dharti Ukani, Mohamad Rawas-Qalaji, Tim D Oury, Renee Hart, Madeline Ellgass, Steven J Mullett, Merritt L Fajt, Sally E Wenzel, Fernando Holguin, Bruce A Freeman, Stacy G Wendell
JournalScientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 17788 (09 07 2021) ISSN: 2045-2322 [Electronic] England
PMID34493738 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2021. The Author(s).
Chemical References
  • Anti-Asthmatic Agents
  • Antigens, Dermatophagoides
  • Bile Acids and Salts
  • Fatty Acids
  • Nitro Compounds
  • Oleic Acids
  • CXA-10
  • glycoursodeoxycholic acid
  • Ursodeoxycholic Acid
  • Glycocholic Acid
Topics
  • Adolescent
  • Adult
  • Animals
  • Anti-Asthmatic Agents (therapeutic use)
  • Antigens, Dermatophagoides (toxicity)
  • Asthma (drug therapy, etiology, metabolism, physiopathology)
  • Bile Acids and Salts (metabolism)
  • Diet, High-Fat (adverse effects)
  • Drug Evaluation, Preclinical
  • Fatty Acids (chemistry, physiology)
  • Female
  • Forced Expiratory Volume
  • Glycocholic Acid (blood)
  • Humans
  • Liver (drug effects, metabolism)
  • Lung (physiopathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Nitro Compounds (therapeutic use)
  • Obesity (complications, metabolism, physiopathology)
  • Oleic Acids (therapeutic use)
  • Respiratory Hypersensitivity (chemically induced, drug therapy, metabolism)
  • Thinness
  • Ursodeoxycholic Acid (analogs & derivatives, blood)
  • Vital Capacity
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: